HEIDELBERG PHARMA AG O.N./ DE000A11QVV0 /
2024-03-28 6:15:11 PM | Chg. -0.16 | Volume | Bid9:58:00 PM | Ask9:58:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
3.02EUR | -5.03% | 23,062 Turnover: 71,523.53 |
3.10Bid Size: 3,000 | 3.20Ask Size: 1,500 | 106.63 mill.EUR | 0.00% | - |
GlobeNewswire
2017-11-16
Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%
GlobeNewswire
2007-11-12
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2007-11-12
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2007-02-05
Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis
GlobeNewswire
2006-10-09
Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients